HCHalil Lutfi Canat

Halil Lutfi Canat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Halil Lutfi Canat has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prostatic Enlargement in Acromegaly Despite Preserved Lower Urinary Tract Function: A Cross‐Sectional Comparative Study

    by Serafettin Kaymak, Halil Lutfi Canat, Aylin Coskun, Muhammed Zeki Cicek, Hamit Yucel Barut, Mutlu Niyazoglu, Esra Hatipoglu

    Background: Acromegaly is characterized by organomegaly driven by chronic GH/IGF‐1 excess, and the prostate gland may be affected as part of this generalized organ enlargement. Although prostatic enlargement has been documented in previous studies, whether it is accompanied by symptomatic or functional impairment and its potential impact on quality of life remain unclear. This study aimed to evaluate prostate‐related changes in male patients with active and remitting acromegaly compared to healthy controls, and to assess their association with lower urinary tract symptoms, mood, and quality of life. Methods: This cross‐sectional study included 57 male patients with acromegaly (25 active, 32 in remission) and 24 healthy male controls of comparable age and BMI. All participants underwent transabdominal prostate ultrasonography, uroflowmetry, and completed the IPSS, SF‐36, PHQ‐9, GAD‐7, and FSS questionnaires. The AcroQoL was administered to the acromegaly group. Correlations between IGF‐1 levels and prostate parameters were analyzed using Spearman's correlation. Results: Patients with acromegaly had a larger median prostate volume (30 vs. 20 mL, p = 0.03), more frequently had a prostate volume exceeding 30 mL (47% vs. 11%, p = 0.004), and more frequently had prostatic calcification (31% vs. 5%, p = 0.03) than controls, despite lower testosterone levels. Within the acromegaly group, a prostate volume exceeding 30 mL was more frequent in active disease than in remission (64% vs. 33%, p = 0.02), whereas median prostate volume did not differ significantly (31 vs. 24.5 mL, p = 0.1). IGF‐1 was correlated with free PSA (rho = 0.29, p = 0.03) but not with total prostate volume (rho = 0.09, p = 0.53). Calcification rates did not differ by remission status. No significant differences were observed in IPSS scores, uroflowmetry parameters, SF‐36, PHQ‐9, GAD‐7, or AcroQoL between groups. Conclusion: Male patients with acromegaly have larger prostate volumes and more frequent prostatic calcification than controls; prostatic enlargement was more frequent in active disease, whereas calcification did not differ by remission status. These structural alterations were not accompanied by differences in lower urinary tract symptoms, uroflowmetry parameters, or quality of life, suggesting that dedicated urologic surveillance may not be warranted in asymptomatic middle‐aged patients.

  • Open Access

    A case of rare metanephric neoplasm resembling renal cell carcinoma: metanephric stromal tumor

    by Cagri Sevik, Akif Erbin, Onuralp Nisli, Osman Can, Ruveyda Erarslan Selcuk, Alper Kocbiyik, Halil Lütfi Canat

    Metanephric neoplasms (MNs) represent an uncommon subset of benign renal tumors, encompassing entities such as metanephric adenoma, metanephric stromal tumor (MST), and metanephric adenofibroma. Despite the limitations of radiological modalities in accurately differentiating these lesions, their characteristic histopathological architecture and unique immunohistochemical markers are crucial for establishing a definitive diagnosis and distinguishing them from other renal malignancies. In this case report, we describe the diagnostic and treatment process for a 25-year-old woman who was incidentally diagnosed with an MST after undergoing a radical nephrectomy, backed by an analysis of recent research.

  • Beyond Statistical Accuracy: Decision Curve Analysis and Single-Center Independent Validation of the SHA.LIN Score for PCNL Outcomes

    by İbrahim Hacıbey, Veysel Sezgin, Abdullah Akdağ, Çağrı Şevik, Emre Yılmaz, Emin Taha Keskin, Halil Lütfi Canat

    Objective: To perform a single-center independent validation of the SHA.LIN score and compare its predictive accuracy and clinical net benefit with the Guy’s Stone Score (GSS), S.T.O.N.E. score, and CROES nomogram in a large cohort of patients undergoing percutaneous nephrolithotomy (PCNL).Materials and Methods: We retrospectively analyzed 271 adult patients undergoing PCNL between 2020 and 2025. Stone-free status (SFS) was defined as the absence of stones or asymptomatic fragments <4 mm on non-contrast computed tomography at 1 month. Predictive performance was assessed using area under the curve (AUC), calibration plots, and Decision Curve Analysis (DCA).Results: The SFS rate was 73.1%. The CROES nomogram demonstrated the highest predictive accuracy (AUC: 0.802, 95% CI: 0.765–0.839), followed by the SHA.LIN score (AUC: 0.756, 95% CI: 0.715–0.797). The SHA.LIN score significantly outperformed both GSS (AUC: 0.719, p=0.023) and S.T.O.N.E. (AUC: 0.690, p<0.0001). In both univariate and multivariable analyses, the CROES nomogram and SHA.LIN score emerged as significant independent predictors of stone-free status, whereas Guy and STONE scores failed to retain significance after multivariable adjustment. In DCA, the SHA.LIN score showed superior net clinical benefit compared with GSS and S.T.O.N.E. across threshold probabilities between 40% and 80%.Conclusion: The SHA.LIN score is a reliable, independently validated single-center tool for predicting PCNL outcomes. Although the CROES nomogram demonstrates high statistical accuracy, the SHA.LIN score provides superior clinical utility and net benefit in decision curve analysis. Furthermore, CROES and SHA.LIN scores remained independent predictors of stone-free status, whereas Guy and STONE scores failed to demonstrate independent predictive value in multivariable analyses. Further prospective studies with larger cohorts are warranted to validate these findings.

  • Is early imaging a pitfall? Effect of [⁶⁸Ga]Ga-PSMA PET/CT timing after biopsy on SUVmax and adverse pathology prediction in low-to-intermediate risk prostate cancer

    by Enes Mustafa Kaya, Burcu Esen Akkaş, Mehmetcan Uluçay, Fuad Aghazada, Halil Lütfi Canat, Harun Özdemir, Merve Şam Özdemir, Nilsen Yıldırım Erdoğan, Meryem Kaya

  • ASO Visual Abstract: Who is at Risk of Residual Tumor and Pathologic Upstaging at Second TURBT in Non–Muscle-Invasive Bladder Cancer?

    by Ramazan Uğur, Berke Demiriz, Onuralp Nişli, Emin Taha Keskin, Süleyman Şahin, Halil Fırat Baytekin, Halil Lutfi Canat

  • Who is at Risk of Residual Tumor and Pathologic Upstaging at a Second TURBT in Non–Muscle-Invasive Bladder Cancer?

    by Ramazan Uğur, Berke Demiriz, Onuralp Nişli, Emin Taha Keskin, Süleyman Şahin, Halil Fırat Baytekin, Halil Lutfi Canat

  • Open Access

    Validation of the Turkish version of the ANDROTEST for detecting male hypogonadism in patients with sexual dysfunction

    by Abdullah Akdag, Enes Aktas, Akif Erbin, Batu Akalin, Halil Lutfi Canat

    Background: Male hypogonadism is an important endocrine cause of sexual dysfunction, yet symptom-based screening tools require cultural and linguistic validation to ensure their reliability across different populations. Aim: To evaluate the diagnostic performance, reliability, and validity of the Turkish version of the ANDROTEST in men presenting with sexual dysfunction. Methods: This prospective observational study included men aged 18-80 years presenting to the andrology outpatient clinic with symptoms of sexual dysfunction between February and November 2025. A control group consisted of age-matched individuals without clinical suspicion of hypogonadism or conditions affecting gonadal function. Participants completed the Turkish versions of Beck Depression Inventory (BDI) and the International Index of Erectile Function (IIEF). The ANDROTEST was translated and culturally adapted using a forward–backward translation process. Diagnostic performance was evaluated using receiver operating characteristic curve analysis, while test–retest reliability was assessed using the intraclass correlation coefficient (ICC). Multivariable logistic regression analysis was performed to identify independent predictors of hypogonadism. Outcomes: The primary outcome was the diagnostic performance of the Turkish ANDROTEST for identifying hypogonadism. Results: A total of 246 participants were included (120 controls and 126 patients with hypogonadism). Hypogonadal patients demonstrated significantly higher body mass index, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and BDI, whereas total testosterone, free testosterone, sex hormone-binding globulin, high-density lipoprotein cholesterol, IIEF scores, and testicular volumes were significantly lower (all P < .05). The Turkish ANDROTEST demonstrated excellent diagnostic performance with an area under the curve of 0.980 (95% CI: 0.958-0.994). The optimal cut-off value of 11 yielded a sensitivity of 95.2% and specificity of 95.0%. In multivariable analysis, ANDROTEST remained an independent predictor of hypogonadism (adjusted OR 1.80, P = .009). Test–retest reliability was excellent (ICC = 0.99), and strong correlations were observed between the ANDROTEST score and IIEF scores, total testosterone levels, and depression scores (all P < .001). Clinical Implications: The Turkish version of the ANDROTEST may serve as a practical screening tool for identifying men at risk of hypogonadism in routine clinical practice. Strengths and Limitations: Strengths include the prospective design and comprehensive evaluation of psychometric and diagnostic performance. Limitations include the single-center design and the case–control structure, which may overestimate diagnostic performance. Conclusion: The Turkish version of the ANDROTEST demonstrated excellent diagnostic performance and strong reliability for identifying male hypogonadism in men with sexual dysfunction, supporting its potential utility as a culturally adapted screening tool in clinical practice.

  • Open Access

    High-Grade Urothelial Carcinoma with Sarcomatoid Differentiation: A Rare Case Presenting with Colonic Metastasis

    by Çağrı Şevik, Onuralp Nişli, Harun Özdemir, Halil Lütfi Canat

    Objective: Urothelial carcinoma with sarcomatoid differentiation is an uncommon but highly aggressive variant of bladder cancer, often diagnosed at advanced stages and associated with poor outcomes. Colonic metastasis from bladder carcinoma is extremely rare, making this case noteworthy. Case presentation: A 68-year-old male presented with macroscopic hematuria and dysuria. Imaging revealed a bladder mass invading the perivesical tissue. Transurethral biopsy confirmed high-grade urothelial carcinoma with sarcomatoid differentiation. During preoperative evaluation, colonoscopy revealed an ulcerated mass in the ascending colon, confirmed as metastatic carcinoma with similar sarcomatoid features. The patient underwent radical cystectomy and right hemicolectomy. Despite surgery and planned chemotherapy, the patient died postoperatively due to clinical deterioration. Conclusions: This case underscores the aggressive nature of sarcomatoid urothelial carcinoma and highlights the potential for rare metastatic patterns, emphasizing the need for multidisciplinary management in atypical presentations.